BioGenerator - Investor Profile and Portfolio

Indalo Therapeutics is a preclinical-stage biotechnology company focused on developing novel treatments for fibrotic diseases. The company was formed from the merger of Antegrin Therapeutics and Cascadia Therapeutics and the consolidation of their respective management teams in Oct 2016. In work published in Nature Medicine, Indalo’s co-founders elucidated the central importance of specific RGD-binding integrins in the aberrant activation of TGF-β. TGF-β is a cytokine that serves as a master regulator of fibrosis and has been implicated in a variety of fibrotic disease states. The company targeting appropriate subsets of RGD-binding integrins may represent an attractive therapeutic strategy. Using a rational drug-design approach, they have developed a portfolio of novel small molecules that bind to targeted integrins with high potency and selectivity. The company claims that compounds in their portfolio have demonstrated strong activity in preclinical models of renal, hepatic, pulmonary, pancreatic, cardiac, muscular, and surgical implant fibrosis when delivered by parenteral and/or oral administration. They intend to exploit these compounds to address unmet needs in multiple therapeutic areas.